OncLive SOSS

New Fixed-Dose Subcutaneous Option for HER2+ Breast Cancer

September 24, 2020
Mark Pegram, MD, Stanford Women's Cancer Center , Chau Dang, MD, Memorial Sloan Kettering Westchester , Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

x